Millennium Management LLC Buys 625,481 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Millennium Management LLC raised its stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 604.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 728,901 shares of the company's stock after acquiring an additional 625,481 shares during the period. Millennium Management LLC owned approximately 0.33% of Sana Biotechnology worth $1,188,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of SANA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company's stock worth $457,000 after purchasing an additional 6,613 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new position in Sana Biotechnology in the fourth quarter worth about $114,000. Integral Health Asset Management LLC lifted its stake in shares of Sana Biotechnology by 11.1% in the fourth quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company's stock worth $3,260,000 after buying an additional 200,000 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Sana Biotechnology in the fourth quarter worth approximately $35,000. Finally, Compass Rose Asset Management LP grew its holdings in shares of Sana Biotechnology by 150.0% during the fourth quarter. Compass Rose Asset Management LP now owns 250,000 shares of the company's stock valued at $408,000 after buying an additional 150,000 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SANA. HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective on the stock in a report on Tuesday, March 18th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a "buy" rating and a $7.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA traded up $0.29 during trading on Friday, hitting $2.84. The company had a trading volume of 5,912,759 shares, compared to its average volume of 3,512,871. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $7.89. The firm has a market capitalization of $640.35 million, a P/E ratio of -2.03 and a beta of 1.78. The stock has a 50 day simple moving average of $1.81 and a 200 day simple moving average of $2.33.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. As a group, analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.